ArticleDiscover oncology2025
Modulation of copper homeostasis and cuproptosis by PDHA1 in acute myeloid leukemia.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute myeloid leukemia (AML) is an aggressive malignancy with poor prognosis. Recent studies highlight cuproptosis, a copper-dependent cell death mechanism, as a potential therapeutic target in cancers. This study investigates the expression and functional significance of CRGs, particularly PDHA1, in AML progression and cuproptosis regulation
methodsWe integrated bioinformatics analysis and experimental validation. Bioinformatics analysis of RNA-seq data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) was performed to identify CRGs associated with AML. Among these, pyruvate dehydrogenase E1 alpha subunit (PDHA1) was selected for further investigation. AML cell lines (Kasumi-1, U937, etc.) were treated with Elesclomol-CuCl2 to induce cuproptosis. PDHA1 was overexpressed via transfection, and its effects on proliferation (CCK-8, spheroid formation), apoptosis (flow cytometry), cell cycle (propidium iodide staining), and copper ion content were assessed. qPCR, Western blot, and glutathione (GSH) assays evaluated gene/protein expression and redox status.
resultsOur analysis revealed that PDHA1 is significantly downregulated in AML tissues compared to normal controls. Overexpression of PDHA1 in AML cell lines led to reduced cell proliferation, increased apoptosis, and G1 phase arrest. Additionally, PDHA1 overexpression was associated with downregulation of Cyclins D1 and D3. Importantly, PDHA1 overexpression enhanced the sensitivity of AML cells to copper-induced cytotoxicity, indicating its potential to modulate cuproptosis.
conclusionThese findings suggest that PDHA1 regulates cuproptosis by modulating copper metabolism and may serve as a potential therapeutic target and biomarker in AML.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.